NEW YORK (GenomeWeb News) – Cellectis today announced two licensing agreements with Iowa State University granting the Paris-based genome engineering firm the rights to use inventions related to TAL effector-nucleases and monomeric TALENs.

The licenses allow Cellectis to use the technology in any field, it said. TALENs are sequence-specific DNA scissors that can be custom engineered to target and modify any gene of interest in any species.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.